Health Boards
Fibroblasts comprise the main cell type of connective tissue, possessing a spindle-shaped morphology, and produce and maintain the extracellular matrix responsible for the structural integrity of tissues and organs and could soon be used to treat psoriasis.
Source: fibrobiologics.com
Quote:
FibroBiologics announced positive IND-enabling updates from its psoriasis research program demonstrating the potential of human dermal fibroblast (HDF) spheroids as a novel therapeutic approach for chronic-relapse psoriasis.
Psoriasis is a serious autoimmune condition affecting over eight million adults in the United States. In many cases, it progresses to psoriatic arthritis, significantly impacting quality of life. FibroBiologics is focused on harnessing fibroblast science to develop therapies that are not just incremental improvements, but durable, scalable solutions for patients.
“In an acute psoriasis model, a single administration of HDF spheroids matched the efficacy of multiple doses of an anti-IL-23 monoclonal antibody. Now, in a chronic-relapse model, that same single treatment has been shown to significantly reduce disease recurrence,” said Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics.
The company is continuing to expand its research, including exploring repeated dosing regimens, systemic and local cytokine profiling, and histopathological assessments of skin lesions. These efforts are designed to deepen understanding of the mechanisms at work and strengthen the foundation for clinical advancement.
“These IND-enabling results are a pivotal milestone on our path to building a category-defining company in regenerative medicine,” said Pete O’Heeron, Founder and Chief Executive Officer at FibroBiologics. “Chronic inflammatory diseases represent a massive, underserved market, and the ability to address them at scale is a generational opportunity. At FibroBiologics, we’re relentlessly focused on durability, safety, and reproducibility—because those are the levers that unlock scalability and market leadership. The breakthroughs our scientists achieve strengthen the evidence base and bring us closer to creating long-term value for both patients and shareholders.”
FibroBiologics is now evaluating whether a single HDF spheroid treatment can be developed to deliver long-term protection against psoriasis relapse, an outcome that would represent not just progress, but a step-change in how chronic inflammatory diseases are treated.
Source: fibrobiologics.com
